Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario Cazzola

Showing results (501-510 of 645) with videos related to

Pageof 65
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 24, 2008
Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromesMatteo Giovanni Della Porta, Luca Malcovati, Emanuela Boveri, et al.
Blood|December 24, 2005
Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disordersFrancesco Passamonti, Elisa Rumi, Daniela Pietra, et al.
Haematologica|December 8, 2010
Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndromeMatteo G Della Porta, Luca Malcovati, Corinna Strupp, et al.
The American Journal of Medicine|November 16, 2004
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemiaFrancesco Passamonti, Elisa Rumi, Ester Pungolino, et al.
Haematologica|June 11, 2011
Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS)Luca Malcovati, Matteo G Della Porta, Corinna Strupp, et al.
American Journal of Hematology|November 5, 2019
Distinct and convergent consequences of splice factor mutations in myelodysplastic syndromesVikas Madan, Jia Li, Siqin Zhou, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 14, 2017
Imatinib and Nilotinib Off-Target Effects on Human NK Cells, Monocytes, and M2 MacrophagesFrancesca Bellora, Alessandra Dondero, Maria Valeria Corrias, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 14, 2007
Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipationElisa Rumi, Francesco Passamonti, Matteo G Della Porta, et al.
British Journal of Haematology|December 15, 2005
Genetic and clinical heterogeneity of ferroportin diseaseL Cremonesi, Laura Cemonesi, Gian Luca Forni, et al.
Pulmonary Pharmacology & Therapeutics|October 5, 2014
Asthma control in severe asthmatics under treatment with omalizumab: a cross-sectional observational study in ItalyFederica Novelli, Manuela Latorre, Letizia Vergura, et al.
Pageof 65

Showing results (501-510 of 645) with videos related to

Sort By:
Pageof 65
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 24, 2008
Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromesMatteo Giovanni Della Porta, Luca Malcovati, Emanuela Boveri, et al.
Blood|December 24, 2005
Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disordersFrancesco Passamonti, Elisa Rumi, Daniela Pietra, et al.
Haematologica|December 8, 2010
Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndromeMatteo G Della Porta, Luca Malcovati, Corinna Strupp, et al.
The American Journal of Medicine|November 16, 2004
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemiaFrancesco Passamonti, Elisa Rumi, Ester Pungolino, et al.
Haematologica|June 11, 2011
Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS)Luca Malcovati, Matteo G Della Porta, Corinna Strupp, et al.
American Journal of Hematology|November 5, 2019
Distinct and convergent consequences of splice factor mutations in myelodysplastic syndromesVikas Madan, Jia Li, Siqin Zhou, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 14, 2017
Imatinib and Nilotinib Off-Target Effects on Human NK Cells, Monocytes, and M2 MacrophagesFrancesca Bellora, Alessandra Dondero, Maria Valeria Corrias, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 14, 2007
Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipationElisa Rumi, Francesco Passamonti, Matteo G Della Porta, et al.
British Journal of Haematology|December 15, 2005
Genetic and clinical heterogeneity of ferroportin diseaseL Cremonesi, Laura Cemonesi, Gian Luca Forni, et al.
Pulmonary Pharmacology & Therapeutics|October 5, 2014
Asthma control in severe asthmatics under treatment with omalizumab: a cross-sectional observational study in ItalyFederica Novelli, Manuela Latorre, Letizia Vergura, et al.
Pageof 65